Micafungin at physiological serum concentrations shows antifungal activity against Candida albicans and Candida parapsilosis biofilms

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 9, 2014, Pages 5581-5584

  Guembe, M ^a,b   Guinea, J ^a,b,c,d   Marcos Zambrano, L J ^a,b   Fernandez Cruz A ^a,b   Pelaez T ^a,b,c,d   Munoz P ^a,b,c,d   Bouza, E ^a,b,c,d  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d SCHOOL OF MEDICINE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MICAFUNGIN; ANTIFUNGAL AGENT; ECHINOCANDIN; LIPOPEPTIDE;

ANTIFUNGAL ACTIVITY; ARTICLE; BIOFILM; BLOOD CULTURE; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; FUNGAL STRAIN; IN VITRO STUDY; NONHUMAN; PLANKTON; PRIORITY JOURNAL; DRUG EFFECTS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST;

ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA ALBICANS; ECHINOCANDINS; HUMANS; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS;

EID: 84906096674     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02738-14     Document Type: Article

References (43)

1. NNIS System 1999. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999. Am. J. Infect. Control 27:520-532. http://dx.doi.org/10.1016/S0196-6553(99)70031-3.
2. Schaberg DR, Culver DH, Gaynes RP. 1991. Major trends in the microbial etiology of nosocomial infection. Am. J. Med. 91(Suppl 2):S72-S75. http://dx.doi.org/10.1016/0002-9343(91)90346-Y.
3. Banerjee SN, Emori TG, Culver DH, Gaynes RP, Jarvis WR, Horan T, Edwards JR, Tolson J, Hernderson T, Martone WJ. 1991. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am. J. Med. 91(Suppl 2):S86 -S89. http://dx.doi.org/10.1016/0002-9343(91)90349-3.
4. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. 1998. National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn. Microbiol. Infect. Dis. 31:327-332. http://dx.doi.org/10.1016/S0732- 8893(97)00240-X. (Pubitemid 28212061)
5. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. 1998. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic. Diagn. Microbiol. Infect. Dis. 30:121-129. (Pubitemid 28102867)
6. Garbino J, Kolarova L, Rohner P, Lew D, Pichna P, Pittet D. 2002. Secular trends of candidemia over 12 years in adult patients at a tertiary care hospital. Medicine 81:425-433. http://dx.doi.org/10.1097/00005792-200211000- 00003. (Pubitemid 35285962)
7. Rodriguez-Creixems M, Munoz P, Martin-Rabadan P, Cercenado E, Guembe M, Bouza E. 2013. Evolution and aetiological shift of catheterrelated bloodstream infection in a whole institution: the microbiology department may act as a watchtower. Clin. Microbiol. Infect. 19:845-851. http://dx.doi.org/10.1111/1469- 0691.12050.
8. Rodriguez-Creixems M, Alcala L, Munoz P, Cercenado E, Vicente T, Bouza E. 2008. Bloodstream infections: evolution and trends in the microbiology workload, incidence, and etiology, 1985-2006. Medicine 87: 234-249. http://dx.doi.org/10.1097/MD.0b013e318182119b.
9. Goldmann DA, Pier GB. 1993. Pathogenesis of infections related to intravascular catheterization. Clin. Microbiol. Rev. 6:176-192.
10. Tortorano AM, Prigitano A, Lazzarini C, Passera M, Deiana ML, Cavinato S, De lUca C, Grancini A, Lo Casco G, Ossi C, Sala E, Montagna MN. 2013. A 1-year prospective survey of candidemia in Italy and changing epidemiology over one decade. Infection 41:655-662. http://dx.doi.org/10.1007/s15010-013-0455-6.
11. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. 1988. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch. Intern. Med. 148:2642-2645. (Pubitemid 19048184)
12. Ramage G, Saville SP, Thomas DP, Lopez-Ribot JL. 2005. Candida biofilms: an update. Eukaryot. Cell 4:633-638. http://dx.doi.org/10.1128/EC.4.4.633-638. 2005. (Pubitemid 40600417)
13. Nett J, Andes D. 2006. Candida albicans biofilm development, modeling a host-pathogen interaction. Curr. Opin. Microbiol. 9:340-345. http://dx.doi.org/10.1016/j.mib.2006.06.007. (Pubitemid 44108718)
14. Kumar CP, Menon T. 2006. Biofilm production by clinical isolates of Candida species. Med. Mycol. 44:99-101. http://dx.doi.org/10.1080/ 13693780500338084. (Pubitemid 43135563)
15. Uppuluri P, Lopez-Ribot JL. 2010. An easy and economical in vitro method for the formation of Candida albicans biofilms under continuous conditions of flow. Virulence 1:483-487. http://dx.doi.org/10.4161/viru.1.6.13186.
16. Negri M, Silva SN, Henriques M, Azeredo J, Svidzinski T, Oliveira RR. 2011. Candida tropicalis biofilms: artificial urine, urinary catheters and flow model. Med. Mycol. 49:739-747. http://dx.doi.org/10.3109/13693786.2011.560619.
17. Silva S, Henriques M, Martins A, Oliveira R, Williams D, Azeredo J. 2009. Biofilms of non-Candida albicans Candida species: quantification, structure and matrix composition. Med. Mycol. 47:681-689. http://dx.doi.org/10.3109/ 13693780802549594.
18. Estivill D, Arias A, Torres-Lana A, Carrillo-Munoz AJ, Arevalo MP. 2011. Biofilm formation by five species of Candida on three clinical materials. J. Microbiol. Methods 86:238-242. http://dx.doi.org/10.1016/j.mimet.2011.05.019.
19. Mukherjee PK, Long L, Kim HG, Ghannoum MA. 2009. Amphotericin B lipid complex is efficacious in the treatment of Candida albicans biofilms using a model of catheter-associated Candida biofilms. Int. J. Antimicrob. Agents. 33:149-153. http://dx.doi.org/10.1016/j.ijantimicag.2008.07.030.
20. Kucharikova S, Tournu H, Holtappels M, Van Dijck P, Lagrou K. 2010. In vivo efficacy of anidulafungin against mature Candida albicans biofilms in a novel rat model of catheter-associated Candidiasis. Antimicrob. Agents Chemother. 54:4474-4475. http://dx.doi.org/10.1128/AAC.00697-10.
21. Lazzell AL, Chaturvedi AK, Pierce CG, Prasad D, Uppuluri P, Lopez-Ribot JL. 2009. Treatment and prevention of Candida albicans biofilms with caspofungin in a novel central venous catheter murine model of candidiasis. J. Antimicrob. Chemother. 64:567-570. http://dx.doi.org/10.1093/jac/dkp242.
22. Tumbarello M, Fiori B, Trecarichi EM, Posteraro P, Losito AR, De Luca A, Sanguinetti M, Fadda G, Cauda R, Posteraro B. 2012. Risk factors and outcomes of candidemia caused by biofilm-forming isolates in a tertiary care hospital. PLoS One 7:e33705. http://dx.doi.org/10.1371/journal.pone.0033705.
23. Al-Fattani MA, Douglas LJ. 2004. Penetration of Candida biofilms by antifungal agents. Antimicrob. Agents Chemother. 48:3291-3297. http://dx.doi.org/10.1128/AAC.48.9.3291-3297.2004. (Pubitemid 39129321)
24. Samaranayake YH, Ye J, Yau JY, Cheung BP, Samaranayake LP. 2005. In vitro method to study antifungal perfusion in Candida biofilms. J. Clin. Microbiol. 43:818-825. http://dx.doi.org/10.1128/JCM.43.2.818-825.2005. (Pubitemid 40256040)
25. Jacobson MJ, Piper KE, Nguyen G, Steckelberg JM, Patel R. 2008. In vitro activity of anidulafungin against Candida albicans biofilms. Antimicrob. Agents Chemother. 52:2242-2243. http://dx.doi.org/10.1128/AAC.00211-08. (Pubitemid 351758568)
26. Ferreira JA, Carr JH, Starling CE, de Resende MA, Donlan RM. 2009. Biofilm formation and effect of caspofungin on biofilm structure of Candida species bloodstream isolates. Antimicrob. Agents Chemother. 53: 4377-4384. http://dx.doi.org/10.1128/AAC.00316-09.
27. Tobudic S, Kratzer C, Lassnigg A, Graninger W, Presterl E. 2010. In vitro activity of antifungal combinations against Candida albicans biofilms. J. Antimicrob. Chemother. 65:271-274. http://dx.doi.org/10.1093/jac/dkp429.
28. Bernhardt H, Knoke M, Bernhardt J. 2011. Efficacy of anidulafungin against biofilms of different Candida species in long-term trials of continuous flow cultivation. Mycoses 54:e821-E827. http://dx.doi.org/10.1111/j.1439-0507. 2011.02036.x.
29. Uppuluri P, Srinivasan A, Ramasubramanian A, Lopez-Ribot JL. 2011. Effects of fluconazole, amphotericin B, and caspofungin on Candida albicans biofilms under conditions of flow and on biofilm dispersion. Antimicrob. Agents Chemother. 55:3591-3593. http://dx.doi.org/10.1128/AAC.01701-10.
30. Cateau E, Rodier MH, Imbert C. 2008. In vitro efficacies of caspofungin or micafungin catheter lock solutions on Candida albicans biofilm growth. J. Antimicrob. Chemother. 62:153-155. http://dx.doi.org/10.1093/jac/dkn160. (Pubitemid 351865889)
31. Seidler M, Salvenmoser S, Muller FM. 2006. In vitro effects of micafungin against Candida biofilms on polystyrene and central venous catheter sections. Int. J. Antimicrob. Agents. 28:568-573. http://dx.doi.org/10.1016/j.ijantimicag. 2006.07.024. (Pubitemid 44779180)
32. Cateau E, Berjeaud JM, Imbert C. 2011. Possible role of azole and echinocandin lock solutions in the control of Candida biofilms associated with silicone. Int. J. Antimicrob. Agents. 37:380-384. http://dx.doi.org/10.1016/j. ijantimicag.2010.12.016.
33. Simitsopoulou M, Peshkova P, Tasina E, Katragkou A, Kyrpitzi D, Velegraki A, Walsh TJ, Roilides E. 2013. Species-specific and drug-specific differences in susceptibility of Candida biofilms to echinocandins: characterization of less common bloodstream isolates. Antimicrob. Agents Chemother. 57:2562-2570. http://dx.doi.org/10.1128/AAC.02541-12.
34. Jacobson MJ, Steckelberg KE, Piper KE, Steckelberg JM, Patel R. 2009. In vitro activity of micafungin against planktonic and sessile Candida albicans isolates. Antimicrob. Agents Chemother. 53:2638-2639. http://dx.doi.org/10.1128/ AAC.01724-08.
35. O'Toole GA. 2011. Microtiter dish biofilm formation assay. J. Vis Exp. 2011(47):489-495. http://dx.doi.org/10.3791/2437.
36. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr, Calandra TF, Edwards JE, Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535. http://dx.doi.org/10.1086/596757.
37. Arendrup MC, Cuenca-Estrella M, Lass-Florl C, Hope W. 2012. EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin. Microbiol. Infect. 18:E246-E247. http://dx.doi.org/10.1111/j.1469-0691.2012.03880.x.
38. Ramage G, Vande Walle K, Wickes BL, Lopez-Ribot JL. 2001. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob. Agents Chemother. 45:2475-2479. http://dx.doi.org/10.1128/ AAC.45.9.2475-2479.2001. (Pubitemid 32801898)
39. Pierce CG, Uppuluri P, Tristan AR, Wormley FL, Jr, Mowat E, Ramage G, Lopez-Ribot JL. 2008. A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nat. Protoc. 3:1494-1500. http://dx.doi.org/10.1038/ nport.2008.141.
40. Nucci M, Anaissie E, Betts RF, Dupont BF, Wu C, Buell DN, Kovanda L, Lortholary O. 2010. Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin. Infect. Dis. 51:295-303. http://dx.doi.org/10.1086/ 653935.
41. Rodriguez D, Park BJ, Almirante B, Cuenca-Estrella M, Planes AM, Mensa J, Gimenez M, Saballs P, Fridkin SK, Rodriguez-Tudela JL, Pahissa A. 2007. Impact of early central venous catheter removal on outcome in patients with candidaemia. Clin. Microbiol. Infect. 13:788-793. http://dx.doi.org/10.1111/j. 1469-0691.2007.01758.x. (Pubitemid 47039912)
42. Catalan-Gonzalez M, Carlos Montejo-Gonzalez J. 2009. Pharmacodynamics and pharmacokinetics of micafungin in adults, children and neonate. Rev. Iberoam Micol. 26:23-34. (In Spanish.) http://dx.doi.org/10.1016/S1130-1406(09)70005-1.
43. Mukai T, Nakahara T, Uematsu T, Azuma J. 2001. Pharmacokinetics of FK463, a novel echinocandin analogue, in elderly and non-elderly subjects, abstr A-30. Abstr. 41st Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC). American Society for Microbiology, Washington, DC.